- Home
- MBWM vs COLL Comparison
MBWM vs COLL Comparison
Compare MBWM & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MBWM | COLL |
|---|---|---|
| Founded | 1997 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 986.2M | 1.1B |
| IPO Year | 1997 | 2015 |
Fundamental Metrics
Financial Performance| Metric | MBWM | COLL |
|---|---|---|
| Price | $58.15 | $35.97 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $55.67 | $51.40 |
| AVG Volume (30 Days) | 122.1K | ★ 433.5K |
| Earning Date | 04-21-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.08% | N/A |
| EPS Growth | ★ 10.95 | N/A |
| EPS | ★ 1.32 | 0.40 |
| Revenue | N/A | ★ $780,567,000.00 |
| Revenue This Year | $20.28 | $8.01 |
| Revenue Next Year | $4.67 | N/A |
| P/E Ratio | ★ $44.61 | $90.60 |
| Revenue Growth | N/A | ★ 23.62 |
| 52 Week Low | $42.75 | $29.19 |
| 52 Week High | $59.95 | $50.79 |
Technical Indicators
Market Signals| Indicator | MBWM | COLL |
|---|---|---|
| Relative Strength Index (RSI) | 61.00 | 53.56 |
| Support Level | $48.89 | $33.80 |
| Resistance Level | $59.71 | $38.50 |
| Average True Range (ATR) | 1.58 | 1.41 |
| MACD | -0.02 | -0.04 |
| Stochastic Oscillator | 62.04 | 40.40 |
Price Performance
Historical ComparisonAbout MBWM Mercantile Bank Corporation
Mercantile Bank Corp operates as a bank holding company. It offers various commercial banking services to individuals, businesses, governmental units, and other institutions. These services include deposit products such as checking, savings, and term certificate accounts and lending products such as commercial, residential mortgage, and installment loans. The company generates revenue from interest and dividends earned on loans, securities, and other financial instruments.
About COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. It commercializes its products in the United States, including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively, the Nucynta Products), and Symproic. The company's product portfolio includes Jornay PM, Belbuca, Xtampza ER, Nucynta IR, Nucynta ER, and Symproic.